Same situation, same feeling. I also don’t have high hopes for disruption from some startup, people seem to underestimate how much harder startups in biotech are compared to tech.
As they say, technically correct is the best kind of correct but also the most useless.
Parent's point is well received: it's much harder to be a startup when you need to fund laboratories, complex supply pipelines, diverse and deep know-how, interaction with government agencies etc.